Skip to main content

Table 2 Clinical data of PCa patients analyzed by IHC using TMA with regard to TET1 expression (n = 371 patients in total)

From: Tracing TET1 expression in prostate cancer: discovery of malignant cells with a distinct oncogenic signature

  Count (%) Age (y) PSA (ng/mL)
Median Range Median Range
Low risk 97 (26.2%) 64.6 48.5–78.3 5.74 0.2–38.4
Intermed. risk 45 (12.1%) 64.9 50.6–76.9 12.9 2.9–83.8
High risk 229 (61.7%) 65.5 46.7–77.4 9.9 0.3–113
T2a–c 165 (44.5%) 65.1 46.7–78.3 7.2 0.2–45.1
T3a-b 144 (38.8%) 65.9 54.1–77.4 8.7 0.3–74.8
T4 62 (16.7%) 63.2 50.6–76.5 15.8 2.8–113
GS ≤ 6 73 (19.7%) 64.3 48.5–77.1 5.6 0.2–83.8
GS7 69 (18.6%) 65.6 50.6–78.3 8.0 2.9–50
GS8 147 (39.6%) 66.1 46.7–77.4 10.5 0.3–113
GS ≥ 9 82 (22.1%) 64.6 51.1–77.1 8.8 0.3–65.5
  1. PCa prostate cancer, IHC immunohistochemical analysis, TMA tissue microarray, TET1 ten–eleven translocation family member 1, y years, PSA prostate-specific antigen, T tumor stage, GS Gleason score, Intermed. risk intermediate risk